Last reviewed · How we verify
ZSP1273 Median Dose — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
ZSP1273 Median Dose (ZSP1273 Median Dose) — Guangdong Zhongsheng Pharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ZSP1273 Median Dose TARGET | ZSP1273 Median Dose | Guangdong Zhongsheng Pharmaceutical Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ZSP1273 Median Dose CI watch — RSS
- ZSP1273 Median Dose CI watch — Atom
- ZSP1273 Median Dose CI watch — JSON
- ZSP1273 Median Dose alone — RSS
Cite this brief
Drug Landscape (2026). ZSP1273 Median Dose — Competitive Intelligence Brief. https://druglandscape.com/ci/zsp1273-median-dose. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab